Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement

Conclusions In patients undergoing TAVR, AF was associated with a significantly higher rate of all-cause mortality throughout 12 months follow-up. The early safety endpoint in patients with AF on apixaban was significantly less frequent compared with patients receiving a VKA.

http://www.interventions.onlinejacc.org/cgi/content/short/10/1/66?rss=1

Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 1, 2017 Category: Cardiology Authors: Seeger, J., Gonska, B., Rodewald, C., Rottbauer, W., Wöhrle, J. Tags: Structural Source Type: research